<img height="1" width="1" src="https://www.facebook.com/tr?id=901494157838465&amp;ev=PageView &amp;noscript=1">
Skip to content

The Future of Consumer Health: 3 Signals for Pharma and Life Sciences Leaders

Nov 18, 2026 1 min read
Photo credit: National Cancer Institute via Unsplash

What emerging signals should pharma and life sciences leaders have on their radar?

This article is part of Stravito’s article series, The Next Move, where futurist and marketing expert Maria Selting Theorell explores emerging shifts through a strategic foresight lens, what they could mean for businesses, and prompts the questions teams should be asking now to stay ahead.

TL;DR

  • For a broader view of the trends and signals influencing consumer behavior, read our previous deep dive.
  • In this article, we cover signals impacting the pharmaceuticals and life sciences industries. Previously, we covered FMCG, retail and finance.
  • Up next, we will cover media/telecoms.

Will we all have our own digital health twins in the future—virtual replicas of our body’s biology or specific organs—that scan for diseases and provide daily dietary recommendations, or will privacy concerns slow this development? Will progress in longevity science make us live for hundreds of years, and what does that mean for our fertility window?

As science progresses and becomes increasingly holistic, blurring the line between wellness and pharma, with shifting consumer demands, it is clear that pharma and life sciences companies need to monitor this structural shift to stay relevant in the future. In this article, we’ll dive into some signals and macrotrends for leaders to keep an eye on.

A snapshot of some progress at the frontier of life sciences

At the future-gazing event Edge Esmeralda, outside San Francisco, I learned of a small but rapidly growing research field in bioelectricity, discovering the electric language of cells and how they communicate without even touching each other. Fertility science is also mind-boggling. In 2025, scientists created early-stage human embryos from DNA taken from ordinary skin cells, implying a future where infertility is far less of a problem.

Another research field is gaining traction in the light of AI – consciousness research – to understand if AI can become conscious, which the California Institute for Machine Consciousness is currently investigating.

And then there are brain implants that read patients' thoughts to help speech-impaired patients communicate, which also leads to privacy concerns. Now scientists have developed a password-protected solution, in which the patient must think of a password to activate the chip. That makes me wonder: what does that mean for future cybersecurity concerns in pharma?

Handpicked signals from the industry experts – and how to turn them into opportunities

There’s no doubt much is happening in the industry. Hence, I turned to the industry and foresight experts Yi Sherry Zhang, Ph.D. from Buck Institute for Research on Aging, Nextatlas, and Mathias Behn Bjørnhof, Futurist & Director at ANTICIPATE, to share one signal each they believe could significantly impact the pharma and life sciences industries and how companies can turn them into opportunities.

But first, let’s look at three macrotrends impacting the industry right now.

 

3 macrotrends currently impacting consumer health

Stravito is pleased to work with Euromonitor International, the macrotrend insights partner for this signal industry series. Stravito and Euromonitor customers can access Euromonitor’s insights directly through our integrations.

 

Nick Stene, Senior Global Insights Manager at Euromonitor International, highlights three key consumer health macrotrends impacting pharmaceuticals and life sciences right now:

1. Health as the definition of beauty – and product categories are merging

Health and beauty are merging into one space, where products are designed to make you look better by improving your internal health. Collagen, vitamin C, and hyaluronic acid supplements that address skin, hair, and nail health are surging in popularity1.

Korean beauty (K-beauty) brands blend functional nutrition with dermocosmetic science, and beauty claims on supplements launched since mid-2024 have risen sharply. Asia leads the trend, with North America in catch-up mode accelerated by the popularity of K-beauty in the US2.

Brands straddling both sides of the health-beauty line — such as offering complementary ingestible and topical solutions — will unlock faster growth than single-category players.

Question for leaders:

  • Which parts of our portfolio are most exposed to this shift, and which are best positioned to win?

2. Asia drives half of consumer health growth  

Nearly 50% of all global consumer health value gains in 2026 are expected to come from Asia Pacific. China is rebounding faster than expected, while markets like Taiwan and South Korea are rising rapidly in per-capita spending3.

Asia leads in beauty-from-within supplements, protein-as-prevention, and accounts for 60% of the 65+ longevity opportunity. In China, e-commerce penetration for vitamins and supplements (VDS) is 63%, setting the global pace4.

Companies without a credible Asia strategy will miss the single largest pool of incremental revenue. Regional innovation, like South Korea, will increasingly shape global product trends.

Question for leaders:

  • Are we underinvested in Asia relative to where future consumer health growth is headed?

3. GLP-1 is reshaping weight loss categories – and creating new product demand

GLP-1 drug adoption, like Ozempic, suppresses the over-the-counter obesity and traditional weight management demand, while simultaneously creating new supplement needs5. Think high-protein products for lean muscle preservation, probiotics to manage GI side effects, and nutrient-gap formulations. Research is pivoting towards supporting pharmaceutical weight loss rather than competing with it, fundamentally reshaping adjacent categories.

Nutrition products designed to support GLP-1 users are becoming a new category. Ingredient suppliers and supplements that align to clinical protocols could benefit from durable demand. Just don’t ask users to shop in a GLP-1 signposted store zone – they don’t like the label.

Question for leaders:

  • Which parts of our current portfolio are most at risk from GLP-1 disruption?

 

[For a deeper look at the macrotrends shaping the future, read our previous article on consumer behavior. It explores five macroshifts across sectors and three signals that could significantly influence future consumer behavior.]

 

3 emerging signals pharma and life sciences can turn into opportunities

1. Longevity science could fundamentally redefine how we measure success in medicine 

Yi Sherry Zhang, Ph.D, Founder of GenoPalate; Co-Founder of Healthspan Horizons; Executive Director of External Strategy & Partnerships, Price Lab at Buck Institute for Research on Aging

About Healthspan Horizons:

Healthspan Horizons, led by the Price Lab at Buck Institute, is advancing AI-powered scientific wellness by integrating multi-omics, longitudinal health data, and artificial intelligence to develop evidence-based approaches for extending healthy human lifespan.

 

Signal area: Technological, social

What?  Early signals indicate a shift in how success in medicine is measured

Emerging developments in longevity science suggest that the way we define and measure therapeutic success could begin to expand beyond traditional disease-specific outcomes. For decades, therapeutic value has been evaluated mainly by whether a drug treats a specific disease. Longevity science shifts the focus to a broader standard: researchers are increasingly measuring how interventions preserve biological function and extend years of healthy living.

The clearest signal is XPRIZE Healthspan, a $101 million competition that asks teams to demonstrate restoration of muscle, cognitive, and immune function by at least 10 years, with a goal of 20 years, rather than improving a single disease endpoint. (Read about the 2026 finalists here.) This emerging direction is also reflected in initiatives such as ARPA-H, the WHO Decade of Healthy Aging, and FDA’s patient-focused clinical outcomes.

So what?  A new measurement paradigm could disrupt the future of pharma

This signal suggests that pharma may eventually be judged not only by "Did this therapy treat the disease?" but by "Did it meaningfully preserve healthy human function over time?"

Success will depend on combining therapeutics with longitudinal data, AI-driven analytics, and real-world evidence that demonstrate improvements in functional health over time.

Organizations that continue to view medicines as standalone products may miss opportunities to partner with emerging health intelligence platforms that integrate therapeutics, longitudinal data, and personalized interventions to demonstrate measurable improvements in healthspan. If this measurement logic gains ground, the implications for clinical evidence, measurement tools, and regulatory infrastructure are substantial.

Now what?  Prepare for a future where medicine is measured on healthy aging

Over the next three to five years, pharmaceutical companies should begin exploring how therapies might be evaluated not only by disease-specific endpoints but also by their contribution to healthy aging.

That means investing earlier in longitudinal cohorts, digital biomarkers, and real-world data infrastructure. It also means building partnerships across diagnostics, wearables, and preventive health rather than treating medicines as standalone products.

Ultimately, the most valuable pharmaceutical companies may be those that help people live longer, healthier lives — not simply survive individual diseases.

Question for leaders:

  • If the definition of therapeutic success expands from treating disease to also preserving function, how should that change what we develop, how we measure value, and where we invest?

 

2. Metabolic health has been associated with mental health conditions 

About Nextatlas:
Nextatlas is a forecasting company built on a proprietary panel of 300,000 early adopters that no general-purpose AI can reach. We spot a trend on average 30 months before it shows up in search, then track its growth so you can move the moment it fits your market.
 
 
Signal area: Technological

What?  A ketogenic diet was associated with improvements in psychiatric symptoms

Researchers in metabolic psychiatry are starting to consider the relationship between mental health conditions – including depression, bipolar disorder, and schizophrenia – and disorders linked to the body’s metabolism. They’ve identified bi-directional interactions between brain chemistry and mitochondrial dysfunction, impaired glucose metabolism, insulin resistance, and chronic inflammation.

Clinical researchers are now testing the ketogenic diet, originally developed for epilepsy, alongside standard psychiatric medication. In one pilot study, patients with bipolar disorder or schizophrenia showed measurable psychiatric improvement while their metabolic markers normalized. This is not fringe science: it suggests a shift from focusing solely on brain chemistry to treating broader health patterns and observing the impact on the mind.

So what?  The mental healthcare market is opening up to non-clinical providers

This signal creates an opportunity for food and nutrition companies, wearable device makers and metabolic drug developers to make defensible claims to beneficial mental health effects they had no chance to make before.

Diet programs, continuous glucose monitors, and metabolic tracking devices could become part of mental health intervention protocols, giving consumer health and wellness brands a credible entry into a market that used to be fenced off for clinical providers.

For pharmaceutical companies specifically, the boundary between "neuro" R&D and "metabolic" R&D is blurring, which most companies' current organizational structures aren't built for. For insurers and healthcare, it raises questions about what should be reimbursed.

If diet and monitoring programs produce measurable psychiatric outcomes, should they be reimbursed by health insurance like medication? This represents a structural competitive shift in the mental health market, where pharma companies are no longer the only credible providers.

Now what?  Pharma should prepare for a new era of interdisciplinary mental healthcare

Over the next three to five years, expect mental health treatment to combine psychiatric drugs increasingly with metabolic interventions and possibly new drugs repurposed from metabolic medicine for psychiatric use.

Pharma companies should prepare by building cross-disciplinary R&D that bridges psychiatry and metabolic medicine and by exploring partnerships with nutrition or wearable companies.

Food and wearable companies have a window to position themselves as legitimate health partners if they generate clinically-measured indications of mental health impact. Insurers will need new reimbursement frameworks for metabolic-based interventions.

Pharma companies that move early to build these interdisciplinary partnerships will be positioned to define new parameters for the mental health market, while slow movers risk losing market share to non-pharma disruptors.

Question for leaders:

  • What would it take for us to lead if the boundaries between psychiatric, metabolic, nutrition, and monitoring sciences start to disappear?

 

3. The measurement of plastic levels in humans could reshape the future of pharma

Mathias Behn Bjørnhof, Futurist & Director, ANTICIPATE

About ANTICIPATE:

ANTICIPATE is a Copenhagen-based strategic foresight consultancy working with corporate, public sector, civil society and education clients internationally. They help organizations scan for change, explore alternative futures, and turn them into decisions they can act on now.

 

Signal area: ecological, technological

What?  Plastic levels become a diagnosis

On 2 April 2026, ARPA-H launched STOMP, a $144M program to build a toolbox for measuring, researching, and affordably removing microplastics and nanoplastics from the human body. What’s notable is that a US health agency has now moved plastic from something we regulate in rivers to something a clinician tests you for and tries to clear.

This came after a Nature Medicine study of post-mortem brain tissue found microplastic concentrations seven to 30 times higher than in liver or kidney tissue samples. The concentration rose over time between 2016 and 2024, and was several times higher again in donors who had dementia.

Most media coverage focused on the “removal” part. However, the bigger signal may be that scientists are building tools to measure plastic in the body and can determine which types of plastic do the most harm. Researchers are candid that no removal claim can be verified until that measurement exists.

So what? Measuring plastic in the body could create a new liability and diagnostics market

Diffuse pollution – pollution spread across many sources – has always been a struggle to prove in court because no one could connect a particular company's product to pollution-related harm in a particular person's body. The case of PFAS, or forever chemicals, has shown that once it is possible to take measurements (in this case, through blood serum testing and epidemiology), a chemical can be turned into a multibillion-dollar settlement category. The science was in place years before the lawsuits and now the same measurement and liability index is being built for plastics.

For life sciences, this prospect could open up a new diagnostics category and a possible removal therapeutic (treatments built around filtering harmful particles out of the blood). On the flip side, this scenario could expose an industry that puts a large quantity of single-use plastic into prefilled syringes, IV bags, inhalers and packaging, and very few companies know their own exposure levels.

This shift spans two megatrends, optimizing health and collapsing ecosystems, which pull in opposite directions. If plastic exposure becomes an individual diagnosis, cost and responsibility may shift from producers to patients, a very large transfer to make by accident.

Now what? Find your exposure before someone else measures it for you

The first marker I would monitor is a validated polymer-specific analysis for human tissue, as commercial testing will almost certainly reach the wellness market before the clinical version is ready. I would expect regulation and litigation to start citing the level of plastic found in people’s bodies instead of plastic levels in water, which is when insurers and employers usually start asking about exposure and screening.

If plastic burden becomes a routine number on a health record, like cholesterol, exposure will become visible and measurable. And once something becomes legible, it gets priced. Materials that release less plastic could become premium priced, while a new detox market may grow for people who can afford testing and treatment.

For pharma and life sciences, the way to prepare is unglamorous: find your own plastic footprint across devices and packaging before somebody measures it for you. Then decide whether you intend to sell the diagnosis, sell the removal, or defend the exposure. Those tracks represent three quite different companies, and most boards have not worked out which one they are.

Question for leaders:

  • If plastic in the body becomes measurable at scale, where are we exposed and where could we lead?

 

The pharma and life sciences industries are no doubt facing an interesting future, with multiple trends and forces converging.

We need to make active decisions on which signals to monitor and act on before it is too late. Decision-making also means sometimes making decisions under uncertainty, since the cost of inaction may be a lot higher.

With Stravito, leaders and innovators can decrease that uncertainty gap by mapping their own company and industry knowledge to the emerging changes they’re monitoring, and make more effective and informed decisions.

The future belongs to those who take an active part in shaping it – and won’t wait until the future has already outrun them. So, what kind of future do you want?

In the next and final article, we’ll cover signals that are impacting the future of the media and telecoms industries.

We’ve also prompted some questions to ask at your next executive meeting below.

 

Executive self-reflection questions

1. If these emerging changes accelerate faster than expected, where is our current portfolio most exposed and where could we lead?
2. Which capabilities do we need to build now — data, partnerships, regulatory, diagnostics, or evidence generation — to stay relevant if category boundaries keep shifting?
3. If new measures of value emerge — from healthspan to metabolic outcomes to exposure diagnostics — how might that change what we develop, how we prove impact, and where we invest?

 


Maria Selting Theorell is a futurist, tech philosopher, fractional CMO and strategic marketing consultant to Stravito. See more about her here.


 

Notes

1Euromonitor International Consumer Health CH2026 Edition

2Euromonitor International Consumer Health CH2026 Edition

3Euromonitor International Consumer Health CH2026 Edition

4Euromonitor International Consumer Health CH2026 Edition

5Euromonitor International Consumer Health CH2026 Edition

 

See how Stravito can help your team

The most valuable insights aren’t the ones sitting in a repository. They’re the ones teams can quickly find, trust, and apply when decisions matter most.

See how Stravito can help your organization turn knowledge into business impact.


In this blog

Author

Image of Maria Selting Theorell
Maria Selting Theorell
Maria is a futurist, tech philosopher and fractional CMO exploring strategic foresight, resilience and how to build brighter futures. As a writer, speaker and podcast host, she curates conversations at the intersection of foresight, technology, philosophy and society. With 15+ years in the tech industry, leading marketing teams at Zettle by PayPal, Lingio and Stravito, she translates complex futures and philosophical ideas into insight leaders can act on. Through her company Phuturist, she offers thought leadership and communication services in foresight, tech and applied philosophy. Previous work includes Stockholm School of Economics, TEDxStockholm, Foresight Institute, Planethon, Philosophy at Work and Berghs School of Communication.